Press Releases

Press Releases

March 24, 2021
CytomX Therapeutics to Host Virtual Investor Event on April 7, 2021
SOUTH SAN FRANCISCO, Calif. , March 24, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody ® technology
Additional Formats
February 19, 2021
CytomX Therapeutics Announces New Employment Inducement Grant
SOUTH SAN FRANCISCO, Calif. , Feb. 19, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally-active antibody therapeutics based on its Probody ® technology platform,
Additional Formats
January 26, 2021
CytomX Therapeutics Announces Closing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. , Jan. 26, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced the completion of its previously announced
Additional Formats
January 19, 2021
CytomX Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. , Jan. 19, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced that it has commenced an underwritten
Additional Formats
Displaying 1 - 10 of 12